EUVIMEDEUVIMED entdecken
Crossref

PRAME/MELAN-A double immunostaining as a diagnostic tool for conjunctival melanocytic lesions: A South American experience

Pedro Carvajal, Pablo Zoroquiain

Pathology - Research and Practice · 2023

DOI: 10.1016/j.prp.2023.154776 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pathology - Research and Practice, 2023. Verfasst von Pedro Carvajal und 1 weiteren Autor:innen. Beteiligte Einrichtung: Pathology Department, School of Medicine, Pontificia Universidad Católica de Chile, Chile. Hauptthemen laut MEDLINE: Conjunctival Neoplasms, Melanoma, Antigens, Neoplasm, MART-1 Antigen. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: Pontificia Universidad Católica de Chile.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: PRAME (PReferentially expressed Antigen in Melanoma) is an antigen that is predominantly expressed in human melanomas. In cutaneous melanocytic lesions, PRAME expression is associated with malignancy. The objective of this study was to evaluate the co-expression of PRAME and Melan A to evaluate their diagnostic value in different conjunctival melanocytic lesions (CML). METHODS: 37 CML (23 nevi, 9 primary acquired melanosis (PAM), and 5 conjunctival melanomas) were evaluated by immunohistochemistry for PRAME and Melan-A. The percentage of melanocytic cells co-expressing PRAME and Melan-A was qualitatively evaluated as follows: negative, 0%; 1 + , 1-25%; 2 + , 26-50%; 3 + , 51-75% and 4 + , ≥ 76%. RESULTS: Of the invasive melanoma cases, 80% showed a 4 + pattern of marking, whereas 20% showed a 3 + pattern. 11% of the PAMs showed a 4 + pattern and 88.9% showed a 1 + pattern. All the nevi showed a 1 + pattern. The sensitivity and specificity of PRAME 4 + for differentiating high-grade CML from the benign and low-grade grouped CML are 93% and 100%, respectively. CONCLUSION: PRAME/MELAN-A double immunostain is particularly useful to differentiate benign from malignant conjunctival melanocytic lesions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Conjunctival NeoplasmsMelanomaAntigens, NeoplasmMART-1 AntigenBiomarkers, TumorMelanosisHumansMaleFemaleImmunohistochemistryMiddle AgedAdultAgedAged, 80 and overDiagnosis, DifferentialSensitivity and Specificity

Stichwörter der Autor:innen

ConjunctivalHMB45ImmunohistochemistryMelanocyticPRAME

Substanzen

PRAME protein, humanAntigens, NeoplasmMART-1 AntigenBiomarkers, TumorMLANA protein, human

Autor:innen und Institutionen

  • Pathology Department, School of Medicine, Pontificia Universidad Católica de Chile, Chile.
  • Pathology Department, School of Medicine, Pontificia Universidad Católica de Chile, Chile. Electronic address: Zoroquiain@gmail.com.

Förderung

  • Pontificia Universidad Católica de Chile

Zitieren

APA

Carvajal, P., & Zoroquiain, P. (2023). PRAME/MELAN-A double immunostaining as a diagnostic tool for conjunctival melanocytic lesions: A South American experience. Pathology - Research and Practice. https://doi.org/10.1016/j.prp.2023.154776

Vancouver

Carvajal P, Zoroquiain P. PRAME/MELAN-A double immunostaining as a diagnostic tool for conjunctival melanocytic lesions: A South American experience. Pathology - Research and Practice. 2023. doi:10.1016/j.prp.2023.154776

BibTeX
@article{Carvajal2023,
  author = {Carvajal, Pedro and Zoroquiain, Pablo},
  title = {PRAME/MELAN-A double immunostaining as a diagnostic tool for conjunctival melanocytic lesions: A South American experience},
  journal = {Pathology - Research and Practice},
  year = {2023},
  doi = {10.1016/j.prp.2023.154776}
}
Kostenlos starten →